For Healthcare Professionals

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)


About the study

Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Histologically confirmed HCC with serum AFP >100ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP >400ng/ml at time of screening and following most current line of therapy.
  2. Metastatic or locally advanced, unresectable HCC
  3. Must have failed or not tolerated at least two (2) different anti-HCC systemic agents
  4. Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant carries at least one HLA-A2 allele
  5. Life expectancy of at least 4 months
  6. Karnofsky Performance Scale greater than or equal to 70
  7. At least 1 measurable lesion on imaging by RECIST
  8. Child-Pugh A6 or better
  9. Absolute neutrophil count greater than or equal to 1,500/mm^3
  10. Platelet count greater than or equal to 75,000/mm^3


Exclusion Criteria:

  1. Clinically significant cardiac disease
  2. Clinically significant pre-existing illness or active infection
  3. Clinically significant Central Nervous System (CNS) or neural dysfunction
  4. Active autoimmune disease requiring therapy
  5. Active malignancy other than HCC with the exception of cholangiocarcinoma (CCA) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement
  6. History of organ transplant
  7. Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction
  8. Advanced HCC involving greater than 50% of the liver
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 510-722-8719Email iconEmail Study Center

Study’s details


Hepatocellular Carcinoma,Liver Cancer,Liver Neoplasm,Metastatic Liver Cancer

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Jun 30, 2024

Treatment type



Eureka Therapeutics Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.